Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -14.35% is 71% above its 5-year average of -49.10%, near the high end of its 5-year range (-69.36%–-14.35%).
70.61% above its 12-month average of -48.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.71%.
RETURN ON ASSETS (ROA)
-14.35%
RETURN ON ASSETS (ROA) AVG TTM
-48.83%
RETURN ON ASSETS (ROA) AVG 3Y
-54.71%
RETURN ON ASSETS (ROA) AVG 5Y
-49.10%
RETURN ON ASSETS (ROA) AVG 10Y
-31.58%
RETURN ON ASSETS (ROA) AVG 15Y
-32.83%
RETURN ON ASSETS (ROA) AVG 20Y
-25.96%
CURRENT VS TTM AVG
+70.61%
CURRENT VS 3Y AVG
+73.77%
CURRENT VS 5Y AVG
+70.77%
CURRENT VS 10Y AVG
+54.56%
CURRENT VS 15Y AVG
+56.29%
CURRENT VS 20Y AVG
+44.72%
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 719 covered companies
CURRENT VS SECTOR MEDIAN
+53.33%
vs the sector median at left
Nektar Therapeutics
Market Cap
$1.16B
Return on Assets (ROA)
-14.35%
TTM Avg
-48.83%
3Y Avg
-54.71%
5Y Avg
-49.10%
Market Cap
$1.15B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.15B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.17B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.14B
Return on Assets (ROA)
-3.98%
TTM Avg
-7.05%
3Y Avg
-9.66%
5Y Avg
-6.44%
Market Cap
$1.14B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.13B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.11B
Return on Assets (ROA)
-117.65%
TTM Avg
-69.65%
3Y Avg
-52.63%
5Y Avg
-41.83%
Market Cap
$1.10B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $1.16B | -14.35% | -48.83% | -54.71% | -49.10% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | -57.23% | -57.23% | -57.23% | -57.23% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 0.69% | 1.67% | 0.18% | -3.47% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -48.35% | -102.84% | -97.55% | -75.48% |
| OPKO Health, Inc. (OPK)vs › | $1.14B | -3.98% | -7.05% | -9.66% | -6.44% |
| Harrow Health, Inc. (HROW)vs › | $1.14B | -8.93% | -2.89% | -5.64% | -7.78% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 4.50% | 8.06% | 9.38% | 7.83% |
| Replimune Group, Inc. (REPL)vs › | $1.11B | -117.65% | -69.65% | -52.63% | -41.83% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.10B | -36.19% | -21.98% | -157.70% | -157.70% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -0.46% | -2.95% | -4.25% | -4.39% |
ROA
-14.3%
ROE
-17.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -58.51% |
| 2024-12-31 | -39.15% |
| 2023-12-31 | -69.36% |
| 2022-12-31 | -51.82% |
| 2021-12-31 | -46.89% |
| 2020-12-31 | -28.88% |
| 2019-12-31 | -22.29% |
| 2018-12-31 | 31.69% |
| 2017-12-31 | -19.00% |
| 2016-12-31 | -26.99% |
| 2015-12-31 | -16.17% |
| 2014-12-31 | -12.21% |
| 2013-12-31 | -37.28% |
| 2012-12-31 | -34.52% |
| 2011-12-31 | -22.09% |
| 2010-12-31 | -7.28% |
| 2009-12-31 | -17.81% |
| 2008-12-31 | -6.13% |
| 2007-12-31 | -4.52% |
| 2006-12-31 | -20.15% |
| 2005-12-31 | -21.56% |
| 2004-12-31 | -13.68% |
| 2003-12-31 | -7.57% |
| 2002-12-31 | -17.72% |
| 2001-12-31 | -37.47% |
| 2000-12-31 | -15.47% |
| 1999-12-31 | -16.95% |
| 1998-12-31 | -13.65% |
| 1997-12-31 | -8.34% |
| 1996-12-31 | -24.10% |
